Premedication for Durvalumab: Not Routinely Required
Routine premedication is not recommended before durvalumab infusion, as the incidence of infusion reactions (IRs) is very low (1-2.2%) and severe reactions occur in less than 1% of patients 1, 2.
Evidence-Based Approach
Standard Practice
- No premedication needed for initial or subsequent durvalumab infusions in most patients 1
- Durvalumab (anti-PD-L1) has one of the lowest IR rates among immune checkpoint inhibitors
- This contrasts sharply with agents like cetuximab (90% IR rate) or daratumumab (40-50% IR rate) that require mandatory premedication 1
When to Consider Premedication
Only after a prior infusion reaction has occurred:
- Antipyretics (acetaminophen) and antihistamines (diphenhydramine) may be considered for subsequent infusions 1, 2
- This is a reactive rather than prophylactic strategy
Clinical Context
The 2017 ESMO guidelines on infusion reaction management specifically state that premedication is not recommended for atezolizumab (another anti-PD-L1 agent with similar IR profile to durvalumab) 1. This same principle applies to durvalumab given its comparable safety profile.
Important distinction: Avelumab (also anti-PD-L1) is the notable exception, requiring premedication with acetaminophen and diphenhydramine for the first 4 infusions due to its 25% IR rate 3, 2. Durvalumab does not share this requirement.
Management of Infusion Reactions If They Occur
Grade 1-2 reactions:
- Stop or slow the infusion rate
- Provide symptomatic treatment
- Resume infusion once stable 1
Grade 3-4 reactions:
- Stop infusion immediately
- Aggressive symptomatic treatment
- Permanently discontinue durvalumab 1
Common Pitfalls to Avoid
- Do not confuse durvalumab with avelumab - only avelumab requires routine premedication among PD-L1 inhibitors
- Do not extrapolate from other monoclonal antibodies - each agent has distinct IR profiles requiring different prophylactic strategies
- Immune-related adverse events are separate from infusion reactions - the management of immune-mediated toxicities (pneumonitis, colitis, etc.) follows different protocols and is not prevented by premedication 3, 2